Ligand Pharmaceuticals | LGND - Debt


Ligand Pharmaceuticals reported $451M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Baxter International USD 9.71B 13M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Enviri Corporation USD 1.44B 3.08M Dec/2024
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.89M 163.33M Dec/2025
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 60.85B 78M Sep/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 40.45M 10.19M Sep/2025